Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | MPO | P05164 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31582707 | 0.81 | KDM4E (0.39) | ESR1MPOALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL27140925 | 0.77 | JAK2 (0.35) | JAK2BTKLMNA | |
| SCHEMBL30847980 | 0.73 | JAK2 (0.30) | JAK2BTK | |
| SCHEMBL28243173 | 0.72 | MPO (0.42) | MPOALDH1A1CYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL31582836 | 0.69 | ESR1 (0.34) | ESR1POLB | |
| SCHEMBL31140840 | 0.67 | ESR1 (0.38) | ESR1MPOALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL18212231 | 0.67 | ESR1 (0.41) | ESR1MPOALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL31698039 | 0.66 | ESR1 (0.40) | ESR1 | |
| SCHEMBL4083412 | 0.66 | NOS1 (0.34) | SMN1; SMN2LMNA | |
| SCHEMBL31582863 | 0.64 | ADORA3 (0.40) | SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025106644-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ALPHA-V BETA-1 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2025-05-22 | — | — | WO | disclosed |